CervoMed (CRVO) Competitors $6.30 +0.43 (+7.33%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$6.36 +0.06 (+0.95%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVO vs. IMAB, CRDF, INBX, MDWD, SOPH, MNPR, SCPH, DSGN, VOR, and ACIUShould you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), scPharmaceuticals (SCPH), Design Therapeutics (DSGN), Vor Biopharma (VOR), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. CervoMed vs. Its Competitors I-Mab Cardiff Oncology Inhibrx Biosciences MediWound SOPHiA GENETICS Monopar Therapeutics scPharmaceuticals Design Therapeutics Vor Biopharma AC Immune I-Mab (NASDAQ:IMAB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Do analysts rate IMAB or CRVO? I-Mab presently has a consensus target price of $6.00, indicating a potential upside of 172.73%. CervoMed has a consensus target price of $22.57, indicating a potential upside of 258.28%. Given CervoMed's higher possible upside, analysts clearly believe CervoMed is more favorable than I-Mab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33CervoMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Do insiders and institutionals believe in IMAB or CRVO? 38.4% of I-Mab shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 35.4% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer IMAB or CRVO? In the previous week, I-Mab and I-Mab both had 2 articles in the media. CervoMed's average media sentiment score of 1.29 beat I-Mab's score of -0.09 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, IMAB or CRVO? CervoMed has higher revenue and earnings than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.89M46.18-$22.23MN/AN/ACervoMed$9.74M5.63-$16.29M-$2.18-2.89 Which has more risk & volatility, IMAB or CRVO? I-Mab has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.75, meaning that its stock price is 175% less volatile than the S&P 500. Is IMAB or CRVO more profitable? I-Mab has a net margin of 0.00% compared to CervoMed's net margin of -200.57%. I-Mab's return on equity of -19.81% beat CervoMed's return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A -19.81% -18.63% CervoMed -200.57%-44.07%-40.65% SummaryI-Mab and CervoMed tied by winning 7 of the 14 factors compared between the two stocks. Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVO vs. The Competition Export to ExcelMetricCervoMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.08M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-2.8920.8026.9720.11Price / Sales5.63286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book1.407.487.985.56Net Income-$16.29M-$55.04M$3.16B$248.40M7 Day Performance13.31%2.44%2.36%4.67%1 Month Performance-18.60%1.90%2.15%6.64%1 Year Performance-58.74%4.35%33.78%21.31% CervoMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVOCervoMed3.1853 of 5 stars$6.30+7.3%$22.57+258.3%-59.2%$51.08M$9.74M-2.894News CoveragePositive NewsIMABI-Mab2.728 of 5 stars$2.42-5.8%$6.00+147.9%+41.0%$209.87M$3.89M0.00380Gap UpCRDFCardiff Oncology1.6864 of 5 stars$3.15flat$9.88+213.5%+77.5%$209.56M$680K0.0020News CoverageAnalyst ForecastINBXInhibrx Biosciences0.9893 of 5 stars$14.27-1.1%N/A+46.5%$208.89M$200K0.12166News CoverageMDWDMediWound1.619 of 5 stars$19.37+0.6%$31.80+64.2%+0.1%$208.16M$20.22M0.0080SOPHSOPHiA GENETICS2.3499 of 5 stars$3.10+0.3%$7.00+125.8%-21.2%$206.06M$65.17M0.00520News CoveragePositive NewsMNPRMonopar Therapeutics2.8969 of 5 stars$35.78+6.5%$56.50+57.9%+940.0%$205.47MN/A0.0010News CoverageAnalyst ForecastGap UpSCPHscPharmaceuticals4.1364 of 5 stars$3.81-1.6%$14.00+267.5%-9.4%$204.30M$36.33M0.0030DSGNDesign Therapeutics0.3745 of 5 stars$3.37-5.6%$4.00+18.7%+4.0%$202.66MN/A0.0040Positive NewsVORVor Biopharma3.9425 of 5 stars$1.62+52.8%$5.63+247.4%+164.9%$202.44MN/A-0.98140Options VolumeGap UpHigh Trading VolumeACIUAC Immune2.7562 of 5 stars$2.03+1.0%$12.00+491.1%-40.5%$201.82M$31.02M0.00140 Related Companies and Tools Related Companies IMAB Alternatives CRDF Alternatives INBX Alternatives MDWD Alternatives SOPH Alternatives MNPR Alternatives SCPH Alternatives DSGN Alternatives VOR Alternatives ACIU Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVO) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
